Cargando…

Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study

OBJECTIVE: Current prevention and/or treatment options for respiratory syncytial virus (RSV) infections are limited as no vaccine is available. Prophylaxis with palivizumab is very expensive and requires multiple intramuscular injections over the RSV season. Here we present proof-of-concept data usi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rajapaksa, Anushi E., Do, Lien Anh Ha, Suryawijaya Ong, Darren, Sourial, Magdy, Veysey, Duncan, Beare, Richard, Hughes, William, Yang, William, Bischof, Robert J., McDonnell, Amarin, Eu, Peter, Yeo, Leslie Y., Licciardi, Paul V., Mulholland, Edward K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466567/ https://www.ncbi.nlm.nih.gov/pubmed/32973520 http://dx.doi.org/10.3389/fphar.2020.01291

Ejemplares similares

Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
por: Edirisinghe, Hasindu S., et al.
Publicado: (2023)

Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy
por: Hentzen, Stijn, et al.
Publicado: (2023)

In vitro Sensitivity Test of Breast Cancer Cells to Hormonal Agents in a Radionucleotide‐incorporation Assay
por: Watanabe, Toru, et al.
Publicado: (1990)

The Medicaid Cost of Palivizumab
por: Ambrose, Christopher S., et al.
Publicado: (2015)

An authentic animal model of the very preterm infant on nasal continuous positive airway pressure
por: Dargaville, Peter A, et al.
Publicado: (2015)

Can data from paediatric cohorts solve the COVID-19 puzzle?
por: Do, Lien Anh Ha, et al.
Publicado: (2020)

Selection of Reference Genes for Gene Expression Studies related to lung injury in a preterm lamb model
por: Pereira-Fantini, Prue M., et al.
Publicado: (2016)

Development of a palivizumab specialty pharmacy management program
por: Harlan, Lana, et al.
Publicado: (2019)

Is immunization with palivizumab really effective in high-risk children?
por: Raguž, Marjana Jerković, et al.
Publicado: (2023)

Studies Recommending Palivizumab Restriction Have Serious Deficiencies
por: Stewart, Dan L.
Publicado: (2010)

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective
por: Homaira, Nusrat, et al.
Publicado: (2014)

Preliminary Proof of the Concept of Wild (Feral) Horses Following Light Aircraft into a Trap
por: McDonnell, Sue, et al.
Publicado: (2020)

Can early measles vaccination control both measles and respiratory syncytial virus infections?
por: Do, Lien Anh Ha, et al.
Publicado: (2022)

Effective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization
por: Rajapaksa, Anushi E, et al.
Publicado: (2014)

Cost effectiveness of palivizumab in Spain: an analysis using observational data
por: Nuijten, Mark J., et al.
Publicado: (2009)

Neonatal outcomes following new reimbursement limitations on palivizumab in Italy
por: Belleudi, Valeria, et al.
Publicado: (2018)

Reappraisal of the Subtropical Guidelines on Palivizumab Prophylaxis in Congenital Heart Disease
por: Chiu, Shuenn-Nan, et al.
Publicado: (2022)

Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era
por: Taylor, Richard S.
Publicado: (2021)

A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis
por: Frogel, Michael
Publicado: (2010)

SARS-CoV-2 infection in children and implications for vaccination
por: Nathanielsz, Jordan, et al.
Publicado: (2022)

Respiratory infections in children up to two years of age on prophylaxis with palivizumab
por: Monteiro, Ana Isabel M. P., et al.
Publicado: (2014)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children
por: al-Alaiyan, Saleh, et al.
Publicado: (2015)

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
por: Olchanski, Natalia, et al.
Publicado: (2018)

Reducing Palivizumab Dose Requirements Through Rational Dose Regimen Design
por: Reuter, Stephanie E., et al.
Publicado: (2018)

Understanding COVID-19 in children may provide clues to protect at-risk populations
por: Do, Lien Anh Ha, et al.
Publicado: (2020)

Impact of Palivizumab on RSV Hospitalizations for Children with Hemodynamically Significant Congenital Heart Disease
por: Chang, Ruey-Kang R., et al.
Publicado: (2009)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008)

Respiratory Syncytial Virus Infection in High-risk Infants – an Update on Palivizumab Prophylaxis
por: Resch, Bernhard
Publicado: (2014)

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
por: Shahabi, Ahva, et al.
Publicado: (2017)

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
por: Resch, Bernhard
Publicado: (2017)

Impact of the use of immunoglobulin palivizumab in the State of São Paulo: a cohort study
por: Gonçalves, Ivana Regina, et al.
Publicado: (2017)

Human respiratory syncytial virus and other viral infections in infants receiving palivizumab
por: Boivin, Guy, et al.
Publicado: (2008)

Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review
por: Belleudi, Valeria, et al.
Publicado: (2021)

Compliance with The RSV Immunoprophylaxis Dosing Schedule in The Polish Registry for Palivizumab (2008-2014)
por: Borecka, Róża, et al.
Publicado: (2019)

Post-translational modifications and glycoprofiling of palivizumab by UHPLC–RPLC/HILIC and mass spectrometry
por: Sran, Kulwinder Singh, et al.
Publicado: (2022)

Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab
por: Manini, Mariana Bueno, et al.
Publicado: (2021)

A post-incorporation study on the use of palivizumab in the Brazilian public health system
por: Batista, Joanna d’Arc Lyra, et al.
Publicado: (2021)

Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children
por: Viguria, Natividad, et al.
Publicado: (2021)

Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
por: Curtiss, Frederic R., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_e3lqr7hmh6kj23pb2i99pqnivf